Sign in

chaelinkim.bsky.social

@chaelinkim.bsky.social
14 followers 19 following 2 posts
PostsRepliesMedia
Reposted by @chaelinkim.bsky.social
Finn McQuaid @cfmcquaid.bsky.social · 31/10/2025
Our framework that informed the @who.int TB & climate change policy brief out now in @lancetrespirmed.bsky.social, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease www.thelancet.com/journals/lan...
thelancet.com
Climate change and tuberculosis: an analytical framework
Climate change is likely to exacerbate a range of determinants that drive tuberculosis, the world's leading cause of death from a single infectious agent. However, tuberculosis is often neglected in w...
12218
Reposted by @chaelinkim.bsky.social
Kate LeGrand @lekate.bsky.social · 17/11/2024
Reflecting on this year’s #TB #UnionConf2024 and am so inspired by the brilliant minds and groundbreaking research being done to combat this global health threat. Special shoutout to the TB Modelling Group @lshtm.bsky.social 🫁
4216
chaelinkim.bsky.social @chaelinkim.bsky.social · 20/10/2025
When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊 doi.org/10.1371/jour...
doi.org
Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis
The WHO recommends the bedaquiline, pretomanid, and linezolid (BPaL) regimen with the additional fluoroquinolone antibiotic moxifloxacin (BPaLM) for initial treatment of multidrug- or rifampicin-resis...
11112